UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 254

Sortiert nach

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Annals of the rheumatic diseases, 2015-07, Vol.74 (7), p.1474-1478

2015

Link zum Volltext

Verfügbarkeit prüfen

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

Annals of the rheumatic diseases, 2016-07, Vol.75 (7), p.1407-1415

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

Arthritis care & research (2010), 2019-03, Vol.71 (3), p.367-378

2019

Link zum Volltext

Verfügbarkeit prüfen

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

Annals of the rheumatic diseases, 2015-04, Vol.74 (4), p.791-792

2015

Link zum Volltext

Verfügbarkeit prüfen

Fluoreszenzoptische Bildgebung zum Nachweis einer möglichen Psoriasisarthritis im Vergleich zum muskuloskelettalen Ultraschall

Journal der Deutschen Dermatologischen Gesellschaft, 2019-09, Vol.17 (9), p.913-922

2019

Link zum Volltext

Verfügbarkeit prüfen

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

The Lancet (British edition), 2017-06, Vol.389 (10086), p.2317-2327

2017

Link zum Volltext

Verfügbarkeit prüfen

The Diagnosis and Treatment of Sjögren's Syndrome

Deutsches Ärzteblatt international, 2017-05, Vol.114 (20), p.354-361

2017

Link zum Volltext

Verfügbarkeit prüfen

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

Annals of the rheumatic diseases, 2022-06, Vol.81 (6), p.881

2022

Link zum Volltext

Verfügbarkeit prüfen

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

The Lancet (British edition), 2016-12, Vol.388 (10061), p.2763-2774

2016

Link zum Volltext

Verfügbarkeit prüfen

Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2

Journal of cellular biochemistry, 2007-05, Vol.101 (1), p.135-146

2007

Link zum Volltext

Verfügbarkeit prüfen

A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro

International journal of molecular sciences, 2020-12, Vol.22 (1), p.128

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2017-10, Vol.69 (10), p.1937-1948

2017

Link zum Volltext

Verfügbarkeit prüfen

Nuclear antigen–reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys

Kidney international, 2021-01, Vol.99 (1), p.238-246

2021

Link zum Volltext

Verfügbarkeit prüfen

Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4+ and CD8+ T cells and macrophages

European journal of immunology, 2017-01, Vol.47 (1), p.180-192

2017

Link zum Volltext

Verfügbarkeit prüfen

Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab

Annals of the rheumatic diseases, 2012-01, Vol.71 (1), p.75-79

2012

Link zum Volltext

Verfügbarkeit prüfen

Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot study

Arthritis research & therapy, 2017-05, Vol.19 (1), p.87-87, Article 87

2017

Link zum Volltext

Verfügbarkeit prüfen

Therapeutische Antikörper in der Rheumatologie

Zeitschrift für Rheumatologie, 2024-03, Vol.83 (2), p.98-104

2024

Link zum Volltext

Verfügbarkeit prüfen

A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients

International journal of molecular sciences, 2017-03, Vol.18 (3), p.583-583

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing

International journal of molecular sciences, 2020-01, Vol.21 (3), p.865

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register

Arthritis research & therapy, 2006-01, Vol.8 (3), p.R66-R66

2006

Link zum Volltext

Verfügbarkeit prüfen

Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity

Arthritis research & therapy, 2018-03, Vol.20 (1), p.44-44, Article 44

2018

Link zum Volltext

Verfügbarkeit prüfen

Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes

International orthopaedics, 2013-01, Vol.37 (1), p.145-151

2013

Link zum Volltext

Verfügbarkeit prüfen

Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus

Proceedings of the National Academy of Sciences - PNAS, 2010-01, Vol.107 (1), p.204-209

2010

Link zum Volltext

Verfügbarkeit prüfen

Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

Arthritis research & therapy, 2019-09, Vol.21 (1), p.209-209, Article 209

2019

Link zum Volltext

Verfügbarkeit prüfen

Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study

Rheumatology (Oxford, England), 2017-09, Vol.56 (9), p.1618-1626

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 254

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(212)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(178)
Life Sciences & Biomedicine
(174)
Humans
(154)
Rheumatology
(132)
Female
(78)
Male
(72)
Adult
(71)
Middle Aged
(68)
Rheumatoid Arthritis
(47)
Biological And Medical Sciences
(46)
Medical Sciences
(45)
Aged
(44)
Immunology
(41)
Diseases Of The Osteoarticular System
(28)
Arthritis, Rheumatoid - Drug Therapy
(27)
Antirheumatic Agents - Therapeutic Use
(25)
Treatment Outcome
(25)
Inflammation
(20)
Cytokines
(19)
Young Adult
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

Fluoreszenzoptische Bildgebung zum Nachweis einer möglichen Psoriasisarthritis im Vergleich zum muskuloskelettalen Ultraschall

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

The Diagnosis and Treatment of Sjögren's Syndrome

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2

A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

Nuclear antigen–reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys

Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4+ and CD8+ T cells and macrophages

Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab

Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot study

Therapeutische Antikörper in der Rheumatologie

A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register

Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity

Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes

Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus

Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study

Suchergebnisse filtern